ARCT · NASDAQ
Arcturus Therapeutics Holdings Inc.
$9.90 -0.97 (-8.92%)
Company overview
Arcturus Therapeutics Holdings Inc. is an RNA medicines company that focuses on the development of vaccines for infectious diseases, as well as liver and respiratory rare diseases, in the United States. The company's development programs include the LUNAR-OTC program for ornithine transcarbamylase deficiency and the LUNAR-CF program for cystic fibrosis lung disease caused by mutations in the cystic fibrosis transmembrane conductance regulator gene. Its vaccine programs include LUNAR-COV19 and LUNAR-FLU. Arcturus has collaboration agreements with Vinbiocare Biotechnology Joint Stock Company for COVID-19 vaccine manufacturing; Janssen Pharmaceuticals Inc. for nucleic acid-based therapeutic candidates targeting hepatitis B; Ultragenyx Pharmaceutical Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $281M
- Employees
- 174
- Headquarters
- San Diego, CA
- Website
- arcturusrx.com
- CEO
- Joseph E. Payne
- Listed
- May 22, 2013
- P/E
- -3.50
- Dividend yield
- 1.29%
Company financials
- Revenue
- $45.4M
- Gross profit
- $41.4M
- Operating income
- -$89.2M
- EBITDA
- -$72.8M
- Net income
- -$78.7M
- EPS
- -$2.83
- Total assets
- $245M
- Total debt
- $19.7M
- Gross margin
- 91.18%
- Net margin
- -173.47%
- Earnings yield
- -28.59%
Showing FY 2025
ARCT
1D
NASDAQ
O9.89H10.89L9.82C10.87+1.33 (+13.94%)Vol495.96K
News